OBJECTIVE: To assess changes in regional brain volumes after 24 months among individuals who initiated combination antiretroviral therapy (cART) within weeks of HIV exposure. DESIGN: Prospective cohort study of Thai participants in the earliest stages of HIV-1infection. METHODS: Thirty-four acutely HIV-infected individuals (AHI; Fiebig I-V) underwent brain magnetic resonance (MR) imaging and MR spectroscopy at 1.5 T and immediately initiated cART. Imaging was repeated at 24 months. Regional brain volumes were quantified using FreeSurfer's longitudinal pipeline. Voxel-wise analyses using tensor-based morphometry (TBM) were conducted to verify regional assessments. Baseline brain metabolite levels, blood and cerebrospinal fluid biomarkers assessed by ELISA, and peripheral blood monocyte phenotypes measured by flow cytometry were examined as predictors of significant volumetric change. RESULTS: Participants were 31 ± 8 years old. The estimated mean duration of infection at cART initiation was 15 days. Longitudinal analyses revealed reductions in volumes of putamen (P < 0.001) and caudate (P = 0.006). TBM confirmed significant atrophy in the putamen and caudate, and also in thalamic and hippocampal regions. In exploratory post-hoc analyses, higher baseline frequency of P-selectin glycoprotein ligand-1 (PSGL-1)-expressing total monocytes correlated with greater caudate volumetric decrease (ρ = 0.67, P = 0.017), whereas the baseline density of PSGL-1-expressing inflammatory (CD14CD16) monocytes correlated with putamen atrophy (ρ = 0.65, P = 0.022). CONCLUSION: Suppressive cART initiated during AHI may not prevent brain atrophy. Volumetric decrease appears greater than expected age-related decline, although examination of longitudinal change in demographically similar HIV-uninfected Thai individuals is needed. Mechanisms underlying progressive HIV-related atrophy may include early activation and enhanced adhesive and migratory capacity of circulating monocyte populations.
OBJECTIVE: To assess changes in regional brain volumes after 24 months among individuals who initiated combination antiretroviral therapy (cART) within weeks of HIV exposure. DESIGN: Prospective cohort study of Thai participants in the earliest stages of HIV-1infection. METHODS: Thirty-four acutely HIV-infected individuals (AHI; Fiebig I-V) underwent brain magnetic resonance (MR) imaging and MR spectroscopy at 1.5 T and immediately initiated cART. Imaging was repeated at 24 months. Regional brain volumes were quantified using FreeSurfer's longitudinal pipeline. Voxel-wise analyses using tensor-based morphometry (TBM) were conducted to verify regional assessments. Baseline brain metabolite levels, blood and cerebrospinal fluid biomarkers assessed by ELISA, and peripheral blood monocyte phenotypes measured by flow cytometry were examined as predictors of significant volumetric change. RESULTS: Participants were 31 ± 8 years old. The estimated mean duration of infection at cART initiation was 15 days. Longitudinal analyses revealed reductions in volumes of putamen (P < 0.001) and caudate (P = 0.006). TBM confirmed significant atrophy in the putamen and caudate, and also in thalamic and hippocampal regions. In exploratory post-hoc analyses, higher baseline frequency of P-selectin glycoprotein ligand-1 (PSGL-1)-expressing total monocytes correlated with greater caudate volumetric decrease (ρ = 0.67, P = 0.017), whereas the baseline density of PSGL-1-expressing inflammatory (CD14CD16) monocytes correlated with putamen atrophy (ρ = 0.65, P = 0.022). CONCLUSION: Suppressive cART initiated during AHI may not prevent brain atrophy. Volumetric decrease appears greater than expected age-related decline, although examination of longitudinal change in demographically similar HIV-uninfected Thai individuals is needed. Mechanisms underlying progressive HIV-related atrophy may include early activation and enhanced adhesive and migratory capacity of circulating monocyte populations.
Authors: Naftali Raz; Karen M Rodrigue; Kristen M Kennedy; Denise Head; Faith Gunning-Dixon; James D Acker Journal: AJNR Am J Neuroradiol Date: 2003-10 Impact factor: 3.825
Authors: R W Price; C T Yiannoutsos; D B Clifford; L Zaborski; A Tselis; J J Sidtis; B Cohen; C D Hall; A Erice; K Henry Journal: AIDS Date: 1999-09-10 Impact factor: 4.177
Authors: Jarek Harezlak; Steven Buchthal; Michael Taylor; Giovanni Schifitto; Jianhui Zhong; Eric Daar; Jeffrey Alger; Elyse Singer; Thomas Campbell; Constantin Yiannoutsos; Ronald Cohen; Bradford Navia Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Philip J Ellery; Emma Tippett; Ya-Lin Chiu; Geza Paukovics; Paul U Cameron; Ajantha Solomon; Sharon R Lewin; Paul R Gorry; Anthony Jaworowski; Warner C Greene; Secondo Sonza; Suzanne M Crowe Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422
Authors: Ann B Ragin; Hongyan Du; Renee Ochs; Ying Wu; Christina L Sammet; Alfred Shoukry; Leon G Epstein Journal: Neurology Date: 2012-11-28 Impact factor: 9.910
Authors: Victor G Valcour; Jintanat Ananworanich; Melissa Agsalda; Napapon Sailasuta; Thep Chalermchai; Alexandra Schuetz; Cecilia Shikuma; Chin-Yuan Liang; Supunee Jirajariyavej; Pasiri Sithinamsuwan; Somporn Tipsuk; David B Clifford; Robert Paul; James L K Fletcher; Mary A Marovich; Bonnie M Slike; Victor DeGruttola; Bruce Shiramizu Journal: PLoS One Date: 2013-07-31 Impact factor: 3.240
Authors: James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater Journal: Elife Date: 2014-09-12 Impact factor: 8.140
Authors: Robert H Paul; Kyu Cho; Andrew Belden; Adam W Carrico; Eileen Martin; Jacob Bolzenius; Patrick Luckett; Sarah A Cooley; Julie Mannarino; Jodi M Gilman; Mariah Miano; Beau M Ances Journal: J Neuroimmune Pharmacol Date: 2022-01-04 Impact factor: 4.147
Authors: Susan Morgello; Korhan Buyukturkoglu; Jacinta Murray; Mike Veenstra; Joan W Berman; Desiree Byrd; Matilde Inglese Journal: J Neuroimaging Date: 2021-09-14 Impact factor: 2.486
Authors: Zeping Wang; Maura M Manion; Elizabeth Laidlaw; Adam Rupert; Chuen-Yen Lau; Bryan R Smith; Avindra Nath; Irini Sereti; Dima A Hammoud Journal: AIDS Date: 2021-07-01 Impact factor: 4.632
Authors: Sarah A Cooley; Jaimie Navid; Julie K Wisch; Anna Boerwinkle; John Doyle; Robert H Paul; Beau M Ances Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771
Authors: Michelle Glans; Sarah A Cooley; Florin Vaida; Anna Boerwinkle; Dimitre Tomov; Kalen J Petersen; Alexander Rosenow; Robert H Paul; Beau M Ances Journal: J Acquir Immune Defic Syndr Date: 2022-05-01 Impact factor: 3.771
Authors: Julian J Weiss; Rachela Calvi; Mika Naganawa; Takuya Toyonaga; Shelli F Farhadian; Michelle Chintanaphol; Jennifer Chiarella; Ming-Qiang Zheng; Jim Ropchan; Yiyun Huang; Robert H Pietrzak; Richard E Carson; Serena Spudich Journal: Clin Infect Dis Date: 2021-10-20 Impact factor: 9.079